AGED Diagnostics

We are a team of geneticists and hepatologists who started our pursuits in 2018 when we realized the tools we were using in research were not being well translated into the clinic. We saw an opportunity to apply genomic innovation to improve the lives of patients. Our team is developing the most accurate blood test for liver disease (also known as nonalcoholic steatohepatitis or NASH).

Learn More

Home (NEW): Welcome

Unmet Medical Needs

While 1 in 3 Americans or 100 million people have liver disease, many are unaware until the disease has progressed to later stages at which point patient outcomes are poor and healthcare spending can cost up to $1,000,000 per patient. Conversely, early detection of liver disease is not only treatable, but fully reversible.

The bronze standard diagnostic tool is a liver biopsy, which is expensive, invasive, prone to sampling error and bleeding. Imaging tools fail in nearly 60% of patients and there are zero accurate noninvasive tools.

60%

Home (NEW): Unmet Medical Needs

Home (NEW): What We Do

Our Business

AGED Diagnostics is using genomic innovation to develop the most accurate blood test for liver disease to help physicians keep patients in the monitoring program, reduce the financial burden for health insurers and improve patient outcomes through early detection and intervention.

Home (NEW): Our Business

What We Do

AGED tools can differentiate benign from advanced liver disease and simultaneously stage fibrosis (liver scarring). Our technology uses a targeted genomic sequencing assessment to measure the concentration of target biomarkers (genetic signatures) in circulation. The presence of biomarkers past a defined concentration indicates a diagnosis of liver disease (NASH) and/or fibrosis.

CORE TECHNOLOGY